mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials.
Saved in:
| Title: | mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials. |
|---|---|
| Authors: | Rotundo MS; Department of Experimental and Clinical Medicine, Medical Oncology, Magna Graecia University, Viale Europa, Catanzaro, Italy., Galeano T; Department of Experimental and Clinical Medicine, Medical Oncology, Magna Graecia University, Viale Europa, Catanzaro, Italy., Tassone P; Department of Experimental and Clinical Medicine, Translational Medical Oncology, Magna Graecia University, Viale Europa, Catanzaro, Italy.; Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia PA, USA., Tagliaferri P; Department of Experimental and Clinical Medicine, Medical Oncology, Magna Graecia University, Viale Europa, Catanzaro, Italy. |
| Source: | Oncotarget [Oncotarget] 2016 May 10; Vol. 7 (19), pp. 27055-66. |
| Publication Type: | Journal Article; Meta-Analysis; Systematic Review |
| Journal Info: | Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Print Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1949-2553 |
|---|---|
| DOI: | 10.18632/oncotarget.7446 |
